1
|
Çiftçi G, Temel HE, Yurttaş L. Apoptotic Effect of Novel Benzimidazole Derivatives Bearing Pyridyl/Pyrimidinyl Piperazine Moiety. Anticancer Agents Med Chem 2021; 22:1780-1792. [PMID: 34238172 DOI: 10.2174/1871520621666210708095110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 05/23/2021] [Accepted: 05/30/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Benzimidazole derivatives bearing pyridyl/pyrimidinyl piperazine moiety has attracted attention in medicinal chemistry and modern drug discovery since it exhibited a variety of biological activities, including anticancer activity. OBJECTIVE In this study, we have designed and synthesized novel 1-[2-oxo-2-(4-substituted phenyl)ethyl]benzimidazol-2-yl)methyl 4-(2-pyridyl/pyrimidin-2-yl)piperazine-1-carbodithioate derivatives (2a-m). We also investigated their anticancer activities against A549 lung adenocarcinoma and C6 rat glioma cell lines and selectivity against NIH/3T3 mouse embryonic fibroblast cell lines. Cholinesterase inhibition effects of these compounds were also measured to investigate the relationship between anticancer activity and cholinesterases. METHOD The cytotoxic activities of these acquired thirteen final compounds were screened using MTT assay on A549, C6, and NIH/3T3 cell lines. Cell proliferation ELISA, BRDU (colorimetric) assay was used for measuring proliferation in replicative cells in which DNA synthesis occurs. Flow cytometric analysis was used for measuring apoptotic cell percentages, caspase 3 activity, and mitochondrial membrane depolarised cell percentages. RESULTS Compounds 2e, 2f, and 2k have been established as the most active antitumor agents with selective cytotoxicities (76.58±6.43, 55.13±5.75, and 32.94±3.02 µM respectively for A549; 86.48±3.60, 97.12±30.21, and 59.29±3.95 µM respectively for C6), high DNA synthesis inhibition rates and high apoptotic cell percentages on both cell lines. CONCLUSION The results have shown that compounds 2e, 2f, and 2k have potential anticancer agents against A549 and C6 cell lines.
Collapse
Affiliation(s)
- Gulsen Çiftçi
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey
| | - Halide Edip Temel
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey
| | - Leyla Yurttaş
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey
| |
Collapse
|
2
|
Cardoso FC, Marliac MA, Geoffroy C, Schmit M, Bispat A, Lewis RJ, Tuck KL, Duggan PJ. The neuronal calcium ion channel activity of constrained analogues of MONIRO-1. Bioorg Med Chem 2020; 28:115655. [DOI: 10.1016/j.bmc.2020.115655] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 07/06/2020] [Accepted: 07/10/2020] [Indexed: 01/19/2023]
|
3
|
|
4
|
Gulcan HO, Mavideniz A, Sahin MF, Orhan IE. Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer’s Disease. Curr Med Chem 2019; 26:3260-3278. [DOI: 10.2174/0929867326666190124123208] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 11/22/2018] [Accepted: 01/01/2019] [Indexed: 12/21/2022]
Abstract
Benzimidazole scaffold has been efficiently used for the design of various pharmacologically active molecules. Indeed, there are various benzimidazole drugs, available today, employed for the treatment of different diseases. Although there is no benzimidazole moiety containing a drug used in clinic today for the treatment of Alzheimer’s Disease (AD), there have been many benzimidazole derivative compounds designed and synthesized to act on some of the validated and non-validated targets of AD. This paper aims to review the literature to describe these benzimidazole containing molecules designed to target some of the biochemical cascades shown to be involved in the development of AD.
Collapse
Affiliation(s)
- Hayrettin Ozan Gulcan
- Eastern Mediterranean University, Faculty of Pharmacy, Division of Pharmaceutical Chemistry, Famagusta, TRNC, via Mersin 10, Turkey
| | - Açelya Mavideniz
- Eastern Mediterranean University, Faculty of Pharmacy, Division of Pharmaceutical Chemistry, Famagusta, TRNC, via Mersin 10, Turkey
| | - Mustafa Fethi Sahin
- Eastern Mediterranean University, Faculty of Pharmacy, Division of Pharmaceutical Chemistry, Famagusta, TRNC, via Mersin 10, Turkey
| | - Ilkay Erdogan Orhan
- Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Etiler, Ankara, Turkey
| |
Collapse
|
5
|
Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain. Future Med Chem 2017; 9:659-671. [DOI: 10.4155/fmc-2016-0237] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: A series of 2-benzylidene-benzofuran-3-ones were designed from the structures of Ebselen analogs and aurone derivatives and synthesized in good yields. Materials & methods: The target compounds were prepared by the condensation reaction between appropriate benzofuranones with amino alkoxy aldehydes and evaluated as cholinesterase inhibitors by Ellman’s method. Results: The in vitro anti-acetylcholinesterase (AChE)/butyrylcholinesterase activities of the synthesized compounds revealed that 7e (IC50 = 0.045 μM) is the most active compound against AChE. Furthermore, the docking study confirmed the results obtained through in vitro experiments and predicted the possible binding conformation. Conclusion: The anticholinesterase activities of benzylidene-benzofurane-3-ones as aurone analogs revealed that the compounds bearing piperidinylethoxy residue showed better activities against AChE, introducing these compounds for further drug discovery developments. [Formula: see text]
Collapse
|
6
|
Yang F, Wu C, Li Z, Tian G, Wu J, Zhu F, Zhang J, He Y, Shen J. A Facile Route of Synthesis for Making Flibanserin. Org Process Res Dev 2016. [DOI: 10.1021/acs.oprd.6b00108] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Feipu Yang
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
| | - Chunhui Wu
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Zhiqiang Li
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Guanghui Tian
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Jianzhong Wu
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Fuqiang Zhu
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Jian Zhang
- Topharman Shanghai Co., Ltd., 1088
Chuansha Road, Shanghai 201209, China
| | - Yang He
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Jingshan Shen
- CAS
Key Laboratory for Receptor Research, Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| |
Collapse
|
7
|
Kralj A, Kurt E, Tschammer N, Heinrich MR. Synthesis and Biological Evaluation of Biphenyl Amides That Modulate the US28 Receptor. ChemMedChem 2013; 9:151-68. [DOI: 10.1002/cmdc.201300369] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 10/23/2013] [Indexed: 11/10/2022]
|
8
|
Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I). Bioorg Med Chem Lett 2013; 23:3416-20. [PMID: 23591110 DOI: 10.1016/j.bmcl.2013.03.080] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 03/18/2013] [Accepted: 03/20/2013] [Indexed: 11/28/2022]
Abstract
A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists. The SAR was explored and the data obtained set up the starting point and foundation for further optimization. The most potent tool compounds, as exemplified by compounds 2l, 5b, 5d, and 5e, displayed antagonism potencies in the subnanomolar range in in vitro human-H3R FLIPR assays and rhesus monkey H3R binding assays.
Collapse
Affiliation(s)
- Zhongli Gao
- LGCR SMRPD Chemical Research, Sanofi US, 153-1-122, 153 2nd Ave, Waltham, MA 02451, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part II). Bioorg Med Chem Lett 2013; 23:3421-6. [DOI: 10.1016/j.bmcl.2013.03.081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 03/18/2013] [Accepted: 03/20/2013] [Indexed: 01/06/2023]
|
10
|
Bansal Y, Silakari O. The therapeutic journey of benzimidazoles: a review. Bioorg Med Chem 2012; 20:6208-36. [PMID: 23031649 DOI: 10.1016/j.bmc.2012.09.013] [Citation(s) in RCA: 519] [Impact Index Per Article: 43.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Revised: 09/07/2012] [Accepted: 09/07/2012] [Indexed: 01/03/2023]
Abstract
Presence of benzimidazole nucleus in numerous categories of therapeutic agents such as antimicrobials, antivirals, antiparasites, anticancer, anti-inflammatory, antioxidants, proton pump inhibitors, antihypertensives, anticoagulants, immunomodulators, hormone modulators, CNS stimulants as well as depressants, lipid level modulators, antidiabetics, etc. has made it an indispensable anchor for development of new therapeutic agents. Varied substitutents around the benzimidazole nucleus have provided a wide spectrum of biological activities. Importance of this nucleus in some activities like, Angiotensin I (AT(1)) receptor antagonism and proton-pump inhibition is reviewed separately in literature. Even some very short reviews on biological importance of this nucleus are also known in literature. However, owing to fast development of new drugs possessing benzimidazole nucleus many research reports are generated in short span of time. So, there is a need to couple the latest information with the earlier information to understand the current status of benzimidazole nucleus in medicinal chemistry research. In the present review, various derivatives of benzimidazole with different pharmacological activities are described on the basis of substitution pattern around the nucleus with an aim to help medicinal chemists for developing an SAR on benzimidazole derived compounds for each activity. This discussion will further help in the development of novel benzimidazole compounds.
Collapse
Affiliation(s)
- Yogita Bansal
- Molecular Modelling Lab, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab 147002, India
| | | |
Collapse
|
11
|
Sander K, Kottke T, Stark H. Histamine H3 Receptor Antagonists Go to Clinics. Biol Pharm Bull 2008; 31:2163-81. [DOI: 10.1248/bpb.31.2163] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Kerstin Sander
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Tim Kottke
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Holger Stark
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| |
Collapse
|